Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
The effect of long-term treatment with tacrine (tetrahydroaminoacridine) was studied in three Alzheimer patients (aged 57, 64, and 68 years) with mild dementia. All three patients had a Mini-Mental State Examination score of 24/30 and carried at least one apolipoprotein E (ApoE) epsilon4 allele. Tacrine was given in doses between 80 and to 160 mg daily for 13-31 months. A lower tacrine concentration was observed generally in cerebrospinal fluid (CSF) compared with plasma. The acetylcholinesterase activity in CSF tended to be increased following longer periods of tacrine treatment, whereas the butyrylcholinesterase activity was decreased. The three patients repeatedly underwent positron emission tomography investigation of cerebral blood flow, nicotinic receptors, cerebral glucose metabolism, and electroencephalogram (EEG) and cognitive tests. Positive influences on these parameters were observed following both short-term and long-term treatment with tacrine. Improvement of nicotinic receptors (measured as 11C-nicotine binding), cerebral blood flow, EEG, and some cognitive tests (trail making test, block design test) occurred earlier after initiation of tacrine treatment compared with the glucose metabolism, which was increased after several months of tacrine treatment. An improvement in attention (trail making test) was observed following tacrine as sign for frontal lobe activation (EEG). The functional effects of tacrine in Alzheimer patients appeared to be related to both dose and length of cholinesterase inhibitor treatment.
Nordberg
A
A
Department of Clinical Neuroscience and Family Medicine, Geriatric Medicine, Karolinska Institutet, Huddinge University Hospital, Sweden.
Amberla
K
K
Shigeta
M
M
Lundqvist
H
H
Viitanen
M
M
Hellström-Lindahl
E
E
Johansson
M
M
Andersson
J
J
Hartvig
P
P
Lilja
A
A
Långström
B
B
Winblad
B
B
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D001786:Blood Glucose / Q000378:metabolism*; D001921:Brain / Q000098:blood supply*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008609:Mental Status Schedule; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011978:Receptors, Nicotinic / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects; D013619:Tacrine / Q000008:administration & dosage* / Q000009:adverse effects
D001786:Blood Glucose; D018697:Nootropic Agents; D011978:Receptors, Nicotinic; D013619:Tacrine